AARD
Aardvark Therapeutics, Inc. Common StockNASDAQHealthcare$4.30+5.13%ClosedMarket Cap: $93.8M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.84
P/S
0.00
EV/EBITDA
-0.71
DCF Value
$2.29
FCF Yield
-60.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-44.6%
ROA
-49.1%
ROIC
-58.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-18.7M | $-17.6M | $-0.81 | — |
| FY 2025 | $0.00 | -Infinity% | $-62.7M | $-57.6M | $-2.93 | — |
| Q3 2025 | $0.00 | -Infinity% | $-17.7M | $-16.3M | $-0.75 | — |
| Q2 2025 | $0.00 | NaN% | $-15.8M | $-14.4M | $-0.66 | — |
| Q1 2025 | $0.00 | NaN% | $-10.5M | $-9.3M | $-0.71 | — |
| Q4 2024 | $0.00 | NaN% | $-9.4M | $-8.8M | $-0.68 | — |
| FY 2024 | $0.00 | NaN% | $-22.8M | $-20.6M | $-1.59 | — |
| Q3 2024 | $0.00 | NaN% | $-5.1M | $-4.2M | $-0.32 | — |
| Q2 2024 | $0.00 | NaN% | $-6.1M | $-5.4M | $-2.13 | — |
| Q1 2024 | $0.00 | NaN% | $-2.2M | $-2.2M | $-0.17 | — |
| Q4 2023 | $0.00 | -Infinity% | $-2.2M | $-2.0M | $-0.21 | — |
| FY 2023 | $0.00 | NaN% | $-7.4M | $-7.2M | $-0.56 | — |